Moneycontrol PRO

business

Market size for Natco's Sorafenib drug is sub $100 mn: Religare

While the Sorafenib drug is not a big opportunity for Natco, approval from Kothur plant is a big positive, says Praful Bohra of Religare Capital Markets.

first published: Jun 3, 2016 03:08 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347